Panacea Biotec · NSE: PANACEABIO · BSE: 531349
Q2 FY25 results · Jul–Sep 2024
Panacea Biotec reported revenue from operations of ₹147.35 crore (up 3.0% from Q2 FY24) and net profit of ₹4.71 crore for Q2 FY25 (Jul–Sep 2024), on a consolidated basis.
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 147.35 | 143.02 | +3.0% | 115.72 | +27.3% |
| Other income | 4.65 | 3.23 | +44.0% | 3.80 | +22.4% |
| Total income | 152.00 | 146.25 | +3.9% | 119.52 | +27.2% |
| Profit before tax | 4.76 | (7.78) | Turned profit | (17.05) | Turned profit |
| Net profit for the period | 4.71 | (8.29) | Turned profit | (15.88) | Turned profit |
| Attributable to shareholders of the company | 4.80 | — | — | (15.80) | Turned profit |
| EPS, basic (₹) | 0.77 | (1.35) | Turned profit | (2.59) | Turned profit |
| Net margin (%) | 3.2 | -5.8 | -13.7 |
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 76.64 | 94.59 | −19.0% | 56.88 | +34.7% |
| Other income | 3.41 | 2.13 | +60.1% | 3.80 | −10.3% |
| Total income | 80.05 | 96.72 | −17.2% | 60.68 | +31.9% |
| Profit before tax | 1.30 | 3.20 | −59.4% | (14.98) | Turned profit |
| Net profit for the period | 1.29 | 3.20 | −59.7% | (13.78) | Turned profit |
| EPS, basic (₹) | 0.21 | 0.52 | −59.6% | (2.25) | Turned profit |
| Net margin (%) | 1.7 | 3.4 | -24.2 |
Consolidated
- Filed with BSE
- 14 Nov 2024, 15:09 IST
- Board meeting
- 13 Nov 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 14 Nov 2024, 15:09 IST
- Board meeting
- 13 Nov 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE